Amylin receptor agonist: difference between revisions
Diff·revision 20 → 21·10:46, 5 Sep 2025
Difference between revision 20 and revision 21 of Amylin receptor agonist. 2 lines changed; the page grew by 280 bytes.
| Revision 20 — 17:20, 8 Aug 2025 Peptide_Pete (talk) add see also to the amylin analogue 4,965 bytes ±0 | Revision 21 — 10:46, 5 Sep 2025 ForestPlotFinn (talk) add the peptide length to the infobox 5,245 bytes +280 | ||
|---|---|---|---|
| 32 | The distinction between reversible self-association and irreversible aggregation matters here as it does for acylated peptides: a size-based method run under dissociating conditions can report a clean profile on material that shows high-molecular-weight species under native conditions. See [[Peptide aggregation]]. | 32 | The distinction between reversible self-association and irreversible aggregation matters here as it does for acylated peptides: a size-based method run under dissociating conditions can report a clean profile on material that shows high-molecular-weight species under native conditions. See [[Peptide aggregation]]. |
| 33 | 33 | ||
| + | 34 | A [[Certificate of analysis|certificate]] for an amylin analogue that reports only [[Area percent purity|reverse-phase area percent]] omits the attribute most likely to fail for this chemistry. That is a statement about method coverage rather than about any particular material. | |
| + | 35 | ||
| 34 | == References == | 36 | == References == |
| 35 | {{reflist}} | 37 | {{reflist}} |